Sensile Medical Enters into an Agreement with scPharmaceuticals
News May 01, 2013
Sensile Medical AG has entered into a strategic partnership and supply agreement with scPharmaceuticals LLC to develop and manufacture an automated patch pump that delivers furosemide subcutaneously.
Furosemide is a diuretic that forms the cornerstone of heart failure therapy and is currently used in tablet form or in solution for intravenous administration. scPharmaceuticals has developed a proprietary subcutaneous formulation of furosemide and will use Sensile Medical’s patented SenseCore technology platform to deliver the drug in a patient-friendly and automated way. scPharmaceuticals will start its late-stage clinical development phase in the near future and expects to submit the New Drug Application for the furosemide drug device combination not later than Q1 of 2015.
“We are very pleased to enter this collaboration with scPharmaceuticals” said Derek Brandt, CEO of Sensile Medical. “We believe that our micro pump technology has the potential to address some important therapeutic and economic challenges that the medical community is facing today. “
“The Affordable Care Act has created an urgent need for novel therapies that offer benefits comparable to those achieved by intravenously administered drugs in the hospital, but which can be administered anytime anywhere by the patient”, said Pieter Muntendam, MD, President and CEO of scPharmaceuticals, “The SenseCore Micro-Pump technology stands out because of its precision and the unique and cost-effective two component design.”
Under the terms of the agreement, Sensile Medical will design, develop, and manufacture patch pumps for scPharmaceuticals’ proprietary subcutaneous formulation of furosemide. Furthermore, it establishes a strategic partnership between Sensile Medical and scPharmaceuticals to work together to develop further medications utilizing Sensile’s technology platform. Terms of the agreement were not disclosed.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018